Lecanemab (BAN2401) Reduces Amyloid in Alzheimer Disease Across 18-Month Study
May 6th 2021Findings on multiple cognitive end points and biomarkers support lecanemab’s therapeutic concept for the targeting of specific oligomeric species in the process of pathophysiological amyloid generation in Alzheimer disease.
Nipocalimab in Myasthenia Gravis and the Remaining Needs for Patients
May 6th 2021Jeffrey Guptill, MD, MS, MHS, associate professor of neurology at neurologist at Duke University, detailed early positive results for nipocalimab in myasthenia gravis and the urgency to provide more treatment options for patients.
NeuroVoices: Vineet Punia, MD, MS, on Responsive Neurostimulation in Older Adults
May 5th 2021The neurologist from Cleveland Clinic discussed his study presented at AAN 2021 involving the use of responsive neurostimulation in older adults with drug-resistant focal epilepsy and further expanding research in this space.
Evaluating Spinal Muscular Atrophy in the Era of Telehealth
May 3rd 2021Two experts in spinal muscular atrophy (SMA) care, Diana Castro, MD, and Garey H. Noritz, MD, offer tips and demonstrations for screening and diagnosing SMA via telehealth, and they outline resources provided by Cure SMA for families and clinicians who suspect, or have a patient with a diagnosis of, SMA.
AUPN Leadership Minute Episode 10: What Your CEO Wants From You
May 1st 2021Episode 10 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University and Robert C. Byrd Health; and Albert L. Wright, Jr., the president and CEO of West Virginia University Health System. [WATCH TIME: 4 minutes]
Income and Education: Predicting Telehealth Use in Parkinson Disease
May 1st 2021The chief scientific officer of the Parkinson’s Foundation and adjunct associate professor in the Department of Neuroscience and Physiology at New York University School of Medicine discussed the adoption of telemedicine in Parkinson disease care.